Cogenics has introduced a global service for its pharma partners that uses the DMET (Drug Metabolising Enzymes and Transporters) Plus Premier Pack from Affymetrix to examine simultaneously 1,936 drug metabolism markers in 225 genes.
The panel features markers for all US Food and Drug Administration-validated genes and covers more than 90% of the current ADME Core Markers as defined by the PharmaADME group. The new service applies the DMET Plus Premier Pack for standardised, cost-efficient drug safety-related testing in clinical trials, says the company.
Cogenics, a genomic service provider and a division of US-based Beckman Coulter, claims to be the first company to offer this service globally. It delivers the high quality data associated with pharmacogenetic testing by combining DMET microarray and other genotyping data using its bioinformatics capabilities. It collaborated with Affymetrix and Eli Lilly in the development of the previously released DMET Early Access Kit.
"Given our experience and success with the DMET platform, we are excited to make this new solution available to our pharma customers," said Susan Evans, global general manager at Cogenics.
Pharmacogenetics testing has become a routinely used process during drug development, with a particular focus on DMET-related testing during clinical drug development.